Trial reportRadiation oncology (London, England)2026
Preliminary results from a phase II trial of spatially fractionated radiotherapy combined with immunotherapy and anti-angiogenic therapy in patients with bulky solid tumors: early evidence of promising efficacy and favorable safety.
Trial report in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06775678 (A Single-centre Phase II Clinical Study of Spatially Fragmentation Radiotherapy Combined With Low-dose Radiotherapy for Reversal of Immunotherapy Combined With Chemotherapy Resistance in Locally Advanced Inoperable or Advanced Non-small Cell Lung Cancer), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-centre Phase II Clinical Study of Spatially Fragmentation Radiotherapy Combined With Low-dose Radiotherapy for Reversal of Immunotherapy Combined With Chemotherapy Resistance in Locally Advanced Inoperable or Advanced Non-small Cell Lung Cancer
Who cites it
1 citing paper in PubMed.
- SFRT alleviates symptoms associated with bulky advanced cancer: a retrospective single-center cohort analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
background and purposeBulky solid tumors present significant therapeutic challenges. Spatially fractionated radiotherapy (SFRT), a technique delivering alternating high- and low-dose subvolumes, alters the tumor microenvironment while minimizing toxicity. This phase II trial assesses the efficacy and safety of SFRT combined with immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in advanced malignancies. METHODS AND MATERIALS: This prospective phase II trial enrolled 34 patients with bulky solid tumors between October 2024 and July 2025. All patients underwent SFRT using GRID, LATTICE, or Stereotactic central/core ablative radiation therapy techniques. Multimodal therapy, incorporating pre-radiotherapy administration of granulocyte-macrophage colony-stimulating factor and thymalfasin, as well as concurrent ICIs and anti-angiogenic agents during SFRT, was administered according to clinical recommendations and patient preferences. The endpoints were treatment-related adverse events and the objective response rate (ORR). In addition, a prognostic analysis was performed to identify factors associated with clinical outcomes.
resultsAmong the 37 treatment courses in 34 patients, 4 patients did not complete the planned therapy, and 1 was lost to follow-up. The median follow-up duration was 6.0 months. Of the 32 evaluable lesions from patients who completed the study, the ORR was 65.63% (21/32). Of the 22 evaluable patients, 5 (22.73%) exhibited abscopal effects. Common adverse events included anemia (18.92%), followed by skin/mucositis and pneumonia, each occurring in 10.81% of patients.
conclusionsThis phase II trial demonstrates that the multimodal approach of SFRT combined with ICIs and anti-angiogenic agents is a promising strategy for bulky solid tumors, while highlighting the need for larger trials to validate long-term efficacy and refine personalized treatment protocols. (Registry: ClinicalTrials.gov, TRN: NCT06775678, Registration date: 1 October 2024)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.